ライフサイエンスコーパス: coinfect

1 irrhosis (32 HCV-monoinfected and 65 HIV/HCV-coinfected).

2 tested, 36% (337/947) of IMD cases were HIV-coinfected.

3 fected; Pseudomonas aeruginosa infected; and coinfected.

4 ed by the HCV-monoinfected (19%) and HIV/HCV-coinfected (11%) (P = 0.003 across groups).

5 ted a cross-sectional study among 50 HIV/HCV-coinfected, 51 HCV-monoinfected, and 50 HIV-monoinfected

6 in initiators vs nonusers among 7686 HIV/HCV-coinfected, 8155 HCV-monoinfected, 17739 HIV-monoinfecte

7 When two IAVs coinfect a cell, they can exchange genes through reassor

8 ess towards elimination goals within HIV/HCV-coinfected adults in Australia following universal DAA a

9 ficiency virus (HIV)-hepatitis B virus (HBV) coinfected adults starting tenofovir-based antiretrovira

10 observational cohort study included HIV/HCV-coinfected adults with genotype 1 HCV who initiated trea

11 atitis B virus (HBV)/hepatitis C virus (HCV) coinfected and 18.2 among HCV monoinfected (P = .03).

12 Contrary to expectations, HIV/HCV-coinfected and HCV-monoinfected adults had significantly

13 ution of baseline characteristics of HIV/HCV-coinfected and HCV-monoinfected patients.

14 urvival time in a large cohort of HIV/HTLV-1-coinfected and HIV-monoinfected individuals on combinati

15 HIV/HCV-coinfected and HIV-monoinfected women had higher median

16 In HIV/HCV-coinfected and HIV-monoinfected women, higher liver stif

17 o significant differences were found between coinfected and monoinfected cases.

18 found in human immunodeficiency virus (HIV)-coinfected and more recently in HIV-uninfected MSM, espe

19 expansion of HTLV-1-infected lymphocytes in coinfected asymptomatic individuals.

20 y to influenza skews immune responses toward coinfecting bacteria and discover novel modes to prevent

21 ntial mosquito viruses from those present in coinfecting bacteria, fungi, and protists.

22 e defect in the antibody response in infants coinfected being a significantly lower level of anti-gp3

23 and endocarditis in febrile patients who are coinfected by bacteria.

24 Most samples were coinfected by multiple viruses, and the majority of iden

25 iency virus (HIV)-negative cases, HIV type 1-coinfected cases had more prolonged illness, larger lesi

26 In 2025, 92.8% of coinfected cases with loiasis hypermicrofilaremia are pr

27 including human immunodeficiency virus (HIV)-coinfected cases) and rifampicin-resistant tuberculosis.

28 s recessive: genetically mutant progeny from coinfected cells did not display the phenotype.

29 Treatment of coinfected cells with GM-CSF restores bacterial control.

30 ssembly of heterologous gene segments within coinfected cells, and the fitness associated with reasso

31 (i) allows for exchange of gene segments in coinfected cells, termed reassortment, and (ii) necessit

32 These expansions were enhanced in CMV-EBV-coinfected children and were independent of varicella-zo

33 ration of critical drug-drug interactions in coinfected children, as these may significantly impact d

34 A-DR7-restricted CD4(+) T cells from the HIV-coinfected cohort that were specific for epitopes of HCM

35 estimates of recurrence in the high-risk and coinfected cohorts were driven by an increase in reinfec

36 Here we show that in coinfected cultures, AAV2 DNA replication takes place al

37 cific CD4(+) T cells had been activated with coinfected DCs compared to Mtb-infected DCs, and this ef

38 ta, and tumor necrosis factor-alpha, whereas coinfected DCs did not.

39 After coculture with coinfected DCs, M. tuberculosis Ag-specific CD4 T cells

40 In the coinfected group with the same initial count, this rate

41 t statistically nonsignificant among HBV/HCV coinfected (hazards ratio [HR] 1.51; 95% confidence inte

42 Evidence of HR between coinfecting herpesvirus DNA genomes can be found frequen

43 de the opportunity for recombination between coinfecting herpesviruses.

44 o characterize circulating CD4(+) T cells in coinfected HLA-DR7(+) long-term nonprogressor HIV subjec

45 Even if pathogens do not interact, death of coinfected hosts causes net prevalences of individual pa

46 between prevalences means the proportion of coinfected hosts is expected to be higher than multiplic

47 teract, intuition suggests the proportion of coinfected hosts should be the product of the individual

48 s detection of HR between different pairs of coinfecting HSV-1 genomes.

49 we explored if HIV-M. tuberculosis-infected (coinfected) human DCs can dysregulate the M. tuberculosi

50 nhibition of HCV replication in vitro and in coinfected humanized mice also reduced interferon signal

51 une responses warrant further studies in HIV coinfected humans able to control their TB infection.

52 Our study comprised 7229 HIV/HCV-coinfected individuals (68% male, 90% white).

53 erates the progression of HCV disease; thus, coinfected individuals are at high priority for HCV trea

54 iasis prevalence and estimated the number of coinfected individuals at risk of post-ivermectin SAEs i

55 ency virus (HIV) and hepatitis C virus (HCV)-coinfected individuals have declined over the last decad

56 eased transition from latent to active TB in coinfected individuals have not been well elucidated at

57 reported at monthly visits in 3381 HIV/HSV-2-coinfected individuals in a placebo-controlled trial of

58 IL-18 was significantly elevated in coinfected individuals versus both monoinfections (p<0.0

59 where HCV-monoinfected patients and HIV/HCV-coinfected individuals were included if they met: 1) SVR

60 ited generalizability, since the majority of coinfected individuals were not eligible to participate.

61 Genomes of isolate pairs from coinfected individuals were sequenced to determine their

62 d host factors that fuel disease severity in coinfected individuals will help guide the design of eff

63 0% for those with HCV infection, 29.5% among coinfected individuals, and 16.1% for those with neither

64 nterferon-free regimens, particularly in HIV-coinfected individuals, remains unknown.

65 emonstrate enhanced plasma levels of MMPs in coinfected individuals, suggesting a plausible biologica

66 In HIV/HCV-coinfected individuals, the crude incidence of HCC incre

67 important implications for TB control in HIV-coinfected individuals.

68 rogression of inflammatory illnesses seen in coinfected individuals.

69 ts in a multicohort collaboration of HIV/HCV-coinfected individuals.

70 [11 (3.0%) HCV-monoinfected, 8(1.2%) HIV/HCV-coinfected individuals; p=0.013].

71 IgA levels were also significantly lower in coinfected infants 2.5 months postinfection and at the t

72 Reassortment of gene segments between coinfecting influenza A viruses (IAVs) facilitates viral

73 Coinfecting isolate pairs had different genotypic backgr

74 its use in human immunodeficiency virus/HCV coinfected kidney transplant patients.

75 e treated 6 human immunodeficiency virus/HCV coinfected kidney transplant recipients with ledipasvir-

76 In contrast, independent of transplant era, coinfected LT recipients had increased risk for death (a

77 m tuberculosis/simian immunodeficiency virus-coinfected (M. tuberculosis/SIV-coinfected) macaques to

78 TB risk was not decreased in the coinfected macaques treated with ART for 14-63 days, sug

79 pulmonary CD4(+) T cells was observed in all coinfected macaques, a subpopulation of the animals was

80 ciency virus-coinfected (M. tuberculosis/SIV-coinfected) macaques to model M. tuberculosis/HIV coinfe

81 of bacterial control that occurs in HIV-Mtb coinfected macrophages correlates with reduced GM-CSF se

82 cted, 169 767 HCV-infected, and 6628 HIV/HCV-coinfected male veterans aged 40-75 years.

83 scued in IFN-gamma-deficient or in TH2 phase coinfected mice demonstrating the key role of this cytok

84 Furthermore, coinfected mice exhibited significantly more airspace ne

85 ific CD8 T cells adoptively transferred into coinfected mice recapitulated the spectrum of helminth-i

86 Bronchoalveolar lavages (BALs) from coinfected mice showed rapid bacterial proliferation 4 t

87 infection with Clostridioides difficile, we coinfected mice that were colonized with ampicillin-resi

88 ive against gonorrhea in gonorrhea/chlamydia-coinfected mice.

89 d HIV-1 infection and dissemination in HSV-2-coinfected mice.

90 increase pathogenicity, which was tested by coinfecting mice with L. guyanensis and lymphocytic chor

91 ity of these genes cannot be alleviated by a coinfecting microbe.

92 IV disrupts the balance between the host and coinfecting microbes, worsening control of these potenti

93 ated with expanded metabolic capacity of the coinfecting microbes.

94 the groundwork to achieve HCV elimination in coinfected MSM.

95 an immunodeficiency virus-coinfected (TB/SIV-coinfected) nonhuman primates.

96 For each coinfecting pair, isolates were genotypically unrelated,

97 We found that, when segment 4 (HA) of coinfecting parental viruses was modified, there was a s

98 Coinfected participants had lower mean z scores for trab

99 ofosbuvir-based DAA therapy to treat HIV/HCV-coinfected participants pre- or post-liver transplant (L

100 autotaxin levels in HCV-infected and HCV-HIV-coinfected participants, compared with uninfected partic

101 rticipants and with Mac2BP levels in HCV-HIV-coinfected participants, while in HIV-infected individua

102 ut capable of rapidly clearing causative and coinfecting pathogens.

103 tion programs and for host susceptibility to coinfecting pathogens.

104 e used a Markov Model to simulate HIV and TB coinfected patient care in LMICs using both publicly ava

105 iffer for HIV-singly (19.0 +/- 0.4 years) or coinfected patients (20.2 +/- 0.6 years) presenting VL<5

106 for HIV-monoinfected (19.0 +/- 0.4 years) or coinfected patients (20.2 +/- 0.6 years) presenting with

107 , all-oral, pan-GT HCV treatment for HIV-HCV coinfected patients across a broad range of ARV regimens

108 HIV/HCV-coinfected patients and HCV-monoinfected patients with a

109 ssful cART is able to normalize survival for coinfected patients and should be introduced for all coi

110 ssful cART is able to normalize survival for coinfected patients and should be introduced for all coi

111 ficiency virus (HIV)-hepatitis C virus (HCV)-coinfected patients are at high risk of metabolic compli

112 gents has dramatically improved outcomes for coinfected patients as sustained virologic response rate

113 itoring could be reduced in monoinfected and coinfected patients by estimating the probability of mai

114 Cirrhotic HIV/HCV-coinfected patients enrolled in the French National Agen

115 HCV-HIV coinfected patients exhibit rapid progression of liver d

116 640 HIV/HCV-coinfected patients fulfilling the following criteria we

117 Among patients with pVL >50 copies/mL, coinfected patients had a shorter survival time (8.4 +/-

118 Among patients with VL >50 copies-mL, coinfected patients had a shorter survival time (8.4 +/-

119 Deceased coinfected patients had higher initial CD4 count (417 +/

120 Deceased coinfected patients had higher initial CD4 count (417+/-

121 apacity to predict mortality risk in HIV-HCV-coinfected patients has never been investigated.

122 Mycobacterium tuberculosis (Mtb) and HIV in coinfected patients has profoundly impacted global morta

123 n well-selected HCV-monoinfected and HIV-HCV-coinfected patients in a real-world setting.

124 r SVR in a representative cohort of Canadian coinfected patients in clinical care.

125 the pathobiology of liver disease in HCV-HIV coinfected patients in the directly acting antiviral era

126 sk factor for all-cause mortality in HIV-HCV-coinfected patients independently of liver fibrosis and

127 nalyzed HCV treatment outcomes among 255 HCV coinfected patients initiating DAAs between February 201

128 r (OPrD) +/- RBV in HIV/HCV genotype 1 (GT1)-coinfected patients initiating HCV therapy in clinical p

129 Our data suggest that eradication of HCV in coinfected patients is associated not only with a reduct

130 Timely ART initiation in all coinfected patients is crucial.

131 rsening drug-induced liver injury challenges coinfected patients on antiretroviral therapy (ART) init

132 HCV GT1/HIV-1 coinfected patients on stable DRV-containing ART achieve

133 icacy and safety of OBV/PTV/r + DSV + RBV in coinfected patients on stable, DRV-containing antiretrov

134 Consistently, platelets from coinfected patients presented defective secretion of the

135 randomized, open-label ALLY-2 study, HIV-HCV-coinfected patients received 8 or 12 weeks of once-daily

136 munodeficiency virus (HIV)-tuberculosis (TB) coinfected patients receiving concomitant treatment for

137 argue for the prescription of HCV therapy in coinfected patients regardless of fibrosis stage.

138 Over a 2-year period, only 36.0% of HIV/HBV coinfected patients seen in HIV practices completed HCC

139 In patients with serial samples, only MRSA-coinfected patients showed time-dependent increases in a

140 Nevertheless, coinfected patients still have a higher mortality risk a

141 oad and fewer unrelated infections in HIV/TB coinfected patients suggests a more complex interaction

142 , and D-dimer (P = .0444) were also found in coinfected patients than in HIV-positive/CMV-negative su

143 For the 4 studies of HIV/HCV coinfected patients the pooled recurrence rate was 32.02

144 50 copies/mL) is able to improve survival of coinfected patients to levels observed for those monoinf

145 We included adult VL-HIV coinfected patients treated for VL and discharged cured

146 V) reactivation has been reported in HBV-HCV-coinfected patients treated with DAAs.

147 ficiency virus (HIV)/hepatitis C virus (HCV)-coinfected patients treated with interferon (IFN) and ri

148 In coinfected patients undergoing TDF, qHBcrAg/qAnti-HBc co

149 The risk of VL relapse in coinfected patients was high, particularly in those not

150 SVR rates in HIV/HCV GT1-coinfected patients were high.

151 HBV-coinfected patients were more likely to have significant

152 However, in the modern era, 35% of HBV-coinfected patients were not receiving tenofovir.

153 reated human immunodeficiency virus (HIV)-TB coinfected patients were observed.

154 man immunodeficiency virus/hepatitis C virus-coinfected patients who relapsed after receiving 12 week

155 LS at SVR for liver complications in HIV/HCV-coinfected patients with advanced fibrosis treated with

156 apy predicts the clinical outcome of HIV/HCV-coinfected patients with advanced fibrosis.

157 deficiency virus (HIV) and hepatitis C (HCV) coinfected patients with advanced liver disease.

158 ficiency virus (HIV)/hepatitis C virus (HCV)-coinfected patients with cirrhosis have long been consid

159 D4 cell counts >300 cells/microL and HIV/HCV-coinfected patients with counts >350 cells/microL.

160 vasive steatosis biomarkers to help identify coinfected patients with higher mortality risk.

161 ial count, this rate was lower, but 97.6% of coinfected patients with initial counts >350 cells/micro

162 te was 2.1 persons-year (76 deaths, 53 among coinfected patients).

163 te was 2.1 person-years (76 deaths, 53 among coinfected patients).

164 between dengue-infected and HIV plus dengue-coinfected patients, plasma levels of the platelet-deriv

165 ed patients and should be introduced for all coinfected patients, regardless CD4 count.

166 ed patients and should be introduced for all coinfected patients, regardless of CD4 cell count.HIV/hu

167 Among HIV/HCV-coinfected patients, statin initiators had lower risks o

168 and biomarkers of bone remodeling in HIV/HCV coinfected patients.

169 is regimen may lead to high failure rates in coinfected patients.

170 us (HCV) genotype 1 (GT1) treatment in HIV-1 coinfected patients.

171 buvir for acute genotype 1 or 4 HCV in HIV-1-coinfected patients.

172 /microL in 5.7% of monoinfected and 11.1% of coinfected patients.

173 monoinfected and 96.4% (27 of 28) in HIV-HCV-coinfected patients.

174 high virologic efficacy in cirrhotic HIV/HCV-coinfected patients.

175 za virus reassortants can arise in naturally coinfected patients.

176 d regimens for HBV should be prioritized for coinfected patients.

177 ; (3) human immunodeficiency virus (HIV)/HCV coinfected patients.

178 s by antiretroviral (ARV) regimen in HIV-HCV-coinfected patients.

179 approval, small trials were done in HIV-HCV coinfected patients.

180 nfection is believed to decrease survival of coinfected patients.

181 ency of liver function monitoring for HIV-TB coinfected patients.

182 ency of liver function monitoring for HIV-TB coinfected patients.Post hoc analysis of the Starting An

183 at under current strategies, at least 31 000 coinfected people still require treatment for onchocerci

184 10 predicted HBV reactivation in a cohort of coinfected people taking DAAs.

185 cccDNA transcription is reduced in HIV/HBV coinfected people with longer antiviral duration.

186 Treating a random selection of 51% of coinfected persons at baseline decreased the risk by 1.9

187 tudinally: 7 HCV-monoinfected and 12 HIV/HCV-coinfected persons before and after treatment for HCV, 1

188 Monocyte exosomes from coinfected persons increased in microRNA (miR)-19a, miR-

189 Initiation of ART in HIV/HSV-2-coinfected persons is associated with a transient increa

190 eated human immunodeficiency virus (HIV)/HCV coinfected persons is unclear.

191 -2.8% to .6%), with 51% (95% CI, 38%-59%) of coinfected persons receiving DAAs.

192 ficiency virus (HIV)-hepatitis C virus (HCV)-coinfected persons than HIV-monoinfected persons.

193 The 10-year risk difference of treating all coinfected persons with DAAs compared with no treatment

194 we isolated >1100 hepatocytes from 5 HIV/HBV coinfected persons with increasing exposure to HBV antiv

195 plasma HIV-1 viral load (VL) in HIV-1/HSV-2 coinfected persons, and this was proposed to be due to a

196 rpes simplex virus type 2 (HSV-2) in HIV/HSV-coinfected persons, may sustain HIV tissue reservoirs by

197 nd neopterin were decreased in HCV mono- and coinfected persons.

198 than by the class of anchor agent in HIV-HCV-coinfected persons.

199 nor biomarkers of bone remodeling in HIV/HCV-coinfected persons.

200 representing approximately 23% of the total coinfected population in care in Canada.

201 als (DAAs) in predominantly minority HIV/HCV coinfected populations.

202 ent for age, or longitudinal observations in coinfected populations.

203 a role in protection against cCMV in HIV/CMV-coinfected populations.

204 ding opportunities for divergent lineages to coinfect, reassort, and generate new viral genotypes.

205 we show that rhesus macaques experimentally coinfected simultaneously with ZIKV and DENV-2 demonstra

206 f 106 human immunodeficiency virus (HIV)/HBV-coinfected subjects maintained on lamivudine, as well as

207 ted with slower HIV-1 disease progression in coinfected subjects.

208 T using TB and simian immunodeficiency virus-coinfected (TB/SIV-coinfected) nonhuman primates.

209 Trabecular volumetric BMD was lower in coinfected than in HCV- or HIV-monoinfected participants

210 Multiple viruses coinfect the male genital tract, influencing each other'

211 hese viruses, if two closely related viruses coinfect the same host or vector cell, it is possible th

212 s was limited by competition with other MGEs coinfecting the same cell.

213 S. pneumoniae serotype (ST) 6A or 8 and then coinfected them with mouse-adapted H1N1 influenza A viru

214 sought to determine its efficiency in a host coinfected through transmission.

215 o-platelet ratio index [APRI]) among HIV-HCV-coinfected users of modern protease inhibitor (PI)- and

216 45.9% of HCV-infected, and 33.8% of HIV/HCV-coinfected veterans had an indication for statin therapy

217 Nine hundred ninety-six HIV/HCV GT1-coinfected veterans initiated therapy: 757 LDV/SOF, 138

218 inical Case Registry to identify HIV/HCV GT1-coinfected veterans initiating 12 weeks of LDV/SOF +/- R

219 of HCV-infected, 49.1% and 58.5% of HIV/HCV-coinfected veterans recommended).

220 ross-sectional analysis of 6032 (16% HIV/HCV coinfected) Veterans Aging Cohort Study participants enr

221 es intriguing questions about where and when coinfecting viral genomes interact.

222 re, significant protection against unrelated coinfecting viral pathogens can be conferred by combinin

223 terial, we show reassortment between the two coinfecting viruses occurred with high likelihood direct

224 No other coinfecting viruses were detected by RNA sequencing stud

225 reassortment of intact gene segments between coinfecting viruses.

226 movement reduces the rate of HR events among coinfecting viruses.

227 .57) followed by HBV- (8.72) and HCV- (6.10) coinfected vs 1.27 in HIV-monoinfected patients.

228 berculosis (65% human immunodeficiency virus coinfected) were intensively sampled to determine rifamp

229 otal of 279 patients (62% of whom were HIV-1 coinfected) were recruited.

230 ptible pneumococci survive Cm treatment when coinfected with a CAT-expressing strain.

231 to carry out a full replication cycle unless coinfected with a full-length virus.

232 Nonhuman primates (NHPs) coinfected with a mutant simian immunodeficiency virus (

233 Sclerotinia sclerotiorum isolate 328 was coinfected with a strain of Sclerotinia sclerotiorum end

234 actinomycetemcomitans was more abundant when coinfected with allopatric than with sympatric microbes,

235 dren with lower respiratory viral infections coinfected with bacteria had elevated levels of neutroph

236 V, present latently in B cells, which may be coinfected with both viruses.

237 CE Persons with HIV infection are frequently coinfected with chronic herpesviruses, which periodicall

238 Most people living with HIV (PLWH) are coinfected with cytomegalovirus (CMV).

239 In Southeast Asia, people are often coinfected with different species of malaria (Plasmodium

240 Host individuals are often coinfected with diverse parasite assemblages, resulting

241 1 patients, of which at least 9 (42.9%) were coinfected with EBOV.

242 opathogenesis, chickens were monoinfected or coinfected with either virulent M. gallisepticum strain

243 iated herpesvirus (KSHV) and 86% of PELs are coinfected with Epstein-Barr virus (EBV).

244 the etiologic agent, and ~80% of tumors are coinfected with Epstein-Barr virus (EBV).

245 adults infected with HTLV-1, either alone or coinfected with HBV.

246 Both HEV-positive cases were coinfected with HBV.

247 Real world data on patients coinfected with HCV and HIV treated with SOF-based regim

248 dy of liver fibrosis progression in patients coinfected with HCV and HIV, using the well-characterize

249 and provided high rates of SVR12 in patients coinfected with HCV and HIV-1.

250 nant women monoinfected with HCV (n = 17) or coinfected with HCV and human immunodeficiency virus (HI

251 ect has been little investigated in patients coinfected with HCV and human immunodeficiency virus (HI

252 However, outcomes among HIV+ LT recipients coinfected with HCV remain concerning and motivate futur

253 munodeficiency virus (HIV)-infected patients coinfected with hepatitis B (HBV) and C (HCV) viruses ar

254 Those with prior malignancies or coinfected with hepatitis B or human immunodeficiency vi

255 Treatment of patients coinfected with hepatitis C and human immunodeficiency v

256 l cohort study (eight countries), 37 (6%; 32 coinfected with hepatitis C virus [HCV] and five with he

257 A total of 1092 HIV-infected patients (51% coinfected with hepatitis C virus) were included.

258 scription opioid oxymorphone, and 92.3% were coinfected with hepatitis C virus.

259 Among patients coinfected with hepatitis C, aRR of mortality at 5 years

260 placebo-controlled trial among 3408 persons coinfected with HIV and herpes simplex virus type 2.

261 of 84 DENV-infected patients of whom 29 were coinfected with HIV under virological control.

262 All five subjects were coinfected with HIV-1 and a closely related strain of HC

263 Children coinfected with HIV-1 had higher levels of TNF-alpha and

264 5A inhibitor velpatasvir for HCV in patients coinfected with HIV-1.

265 V-infected patients were included, 667 (64%) coinfected with HIV.

266 ls with latent tuberculosis infection (LTBI) coinfected with HIV.

267 nd specificity with samples from 69 patients coinfected with HIV.

268 Human immature DCs coinfected with HIV/Mtb had decreased expression of huma

269 We matched 149 patients coinfected with HTLV-1 (cases) by age at HIV diagnosis a

270 In a longitudinal cohort of women coinfected with human immunodeficiency virus (HIV) and h

271 er fibrosis progresses faster in individuals coinfected with human immunodeficiency virus (HIV) and h

272 e antigen (HBeAg) seroclearance in patients coinfected with human immunodeficiency virus (HIV) and h

273 ffective these drugs will be for individuals coinfected with human immunodeficiency virus (HIV)-HCV.

274 or hepatitis C virus (HCV) excluded patients coinfected with human immunodeficiency virus (HIV).

275 ects of THC on fibrosis progression in women coinfected with human immunodeficiency virus (HIV)/HCV e

276 rosis progression in a large cohort of women coinfected with human immunodeficiency virus (HIV)/HCV.

277 HCV within-host evolution from 4 individuals coinfected with human immunodeficiency virus 1 (HIV-1).

278 epatitis C virus (HCV) infection in patients coinfected with human immunodeficiency virus type 1 (HIV

279 tuberculosis infection, especially in women coinfected with human immunodeficiency virus; (2) evalua

280 ue specimens were collected from individuals coinfected with KSHV and HIV.

281 Chickens coinfected with M. gallisepticum R(low) followed by LPAI

282 ation capacity were compared across children coinfected with MRSA or methicillin-susceptible S. aureu

283 In this study, nonhuman primates were coinfected with Mtb and simian immunodeficiency virus (S

284 t adults and adolescents, including patients coinfected with other sexually transmitted infections (s

285 ctive effect in SIV-infected African monkeys coinfected with pegiviruses, possibly because SIV causes

286 usly shown that 11 patients became naturally coinfected with seasonal H1N1 (A/H1N1) and pandemic H1N1

287 Following treatment, animals were coinfected with simian immunodeficiency virus to assess

288 led chronic genotype 1a HCV-infected persons coinfected with suppressed HIV: 5 of 6 treatment-naive e

289 Patients coinfected with syphilis and human immunodeficiency viru

290 h the human immunodeficiency virus (HIV) are coinfected with the hepatitis C virus (HCV) due to share

291 In the UTI model, mice coinfected with the two species exhibited higher urine p

292 etions were self-collected by nine HIV/HSV-2-coinfected women during ART for 28 days to establish sub

293 Subclinical HSV shedding in HIV/HSV-coinfected women during ART may sustain HIV tissue reser

294 Among 575 HIV/HCV-coinfected women followed for a median of 11 (interquart

295 netics (PK) study assessed DMPA among HIV/TB coinfected women on an efavirenz-based antiretroviral tr

296 Among 686 HIV/HCV-coinfected women, 46.0% reported no alcohol use; 26.8% r

297 In HIV/HCV-coinfected women, hepatic fibrosis accelerates with repr

298 In this large cohort of HIV/HCV-coinfected women, THC was not associated with progressio

299 on may be different between monoinfected and coinfected women.

300 tter predict fibrosis progression in HIV/HCV-coinfected women.